NextCure (NASDAQ:NXTC) Announces Earnings Results

NextCure (NASDAQ:NXTC) announced its quarterly earnings results on Thursday. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07), Zacks reports.

NextCure Price Performance

Shares of NXTC stock opened at $0.75 on Friday. The firm has a 50-day moving average of $0.78 and a 200-day moving average of $1.12. The company has a market cap of $21.01 million, a P/E ratio of -0.36 and a beta of 0.71. NextCure has a one year low of $0.66 and a one year high of $2.57.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $3.00 price target (down previously from $4.00) on shares of NextCure in a research note on Friday.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.